A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
University of Pittsburgh
Novartis
Compugen Ltd
NextCure, Inc.
Second Affiliated Hospital of Guangzhou Medical University
ADC Therapeutics S.A.
Kineta Inc.